Mounjaro manufactured by Eli Lilly and the company’s packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024.
Nurphoto | Nurphoto | Getty images
Eli Lilly On Thursday, he said that he increases the price of his Diabetes drug Mounjaro list in the United Kingdom from September, while President Donald Trump is pressure on drug manufacturers to reduce prices of American medicines and go hiking abroad.
In a statement, Eli Lilly said he had entered into an agreement with the British government to increase the price of the weekly injection list, while “now access” to patients covered by the state -funded health system, the National Health Service or the NHS.
Eli Lilly told CNBC that the price increase would not affect the availability of the drug under the NHS, and that it wants to work with the government to stimulate access. The company added that it does not determine the prices that set by private health care providers, but works with them to guarantee access to Mounjaro.
In a press release on Thursday, NHS said that the price increase in the Mounjaro list “will not affect the NHS of shooting in England for eligible people living with obesity, depending on clinical priority or as a treatment for type 2 diabetes”. The shooting is the active ingredient of Mounjaro and his counterpart for weight loss, Zepbound.
The price of the current list of Mounjaro in the United Kingdom varies from £ 92 (around $ 124.89) to £ 122 per month, depending on the dose size, according to Eli Lilly. The new price of the drug list will increase between 133 and £ 330 from September 1.
The company added that it worked with certain governments and plans to make prices adjustments in these countries on this date. In the United States, the price of the list for one month of the Mounjaro offer is $ 1,079.77 before insurance and other discounts.
Eli Lilly said he was supporting the Trump administration’s objective of keeping the United States the “world’s leading destination for biopharmaceutical research and manufacturing, and the objective of sharing revolutionary medical research in developed countries more equitably”.
“This rebalancing can be difficult, but this means that the prices of drugs paid by governments and health systems must increase in other developed markets such as Europe in order to reduce them in the United States,” the company said in the press release.
The announcement comes after Trump in July sent separate letters to 17 drug manufacturers, including Eli Lilly, calling them to take measures to reduce the prices of medicines by September 29. The decision based on the president’s decree in May strengthening a controversial plan – the “most favored” policy – which aims to reduce the costs of drugs by linking the prices of certain drugs in the United States to decrease considerably abroad.
The prices of American prescription drugs are two to three times higher on average than those of other developed countries – and up to 10 times more than in certain countries, according to Rand Corp., a group for reflection on public policy. Trump said he wanted to reduce this gap to prevent Americans from being “scammed”.
Eli Lilly’s announcement comes on Thursday while the industry is based on Trump’s planned prices on imported pharmaceutical products in the United States in its declaration, the company said that it is opposed to these prices, arguing that they will “increase costs, limit patient access and undermine American leadership, in particular for companies that are already investing in national manufacturing.”
In recent months, Eli Lilly has been among several drug manufacturers to announce new plans to invest in American manufacturing sites.